StockMarketNews.Today – Young patients could begin receiving Kymriah, which has a list price of about 282,000 pounds ($363,000), within weeks, England’s National Health Service said in a statement Wednesday. The accord comes just days after a similar therapy, Gilead Sciences Inc.’s Yescarta, was rejected in the U.K. for treatment of a different type of cancer.
Novartis chairman says Alcon worth $20 billion-$30 billion. The Basel-based company will also repurchase up to $5 billion in shares through the end of next year.
ZURICH (Reuters) – The chairman of Swiss drugmaker Novartis (NOVN.S) expects Alcon to be valued at between $20 billion and $30 billion when the opthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft.